Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis

Launched by INDONESIA UNIVERSITY · Dec 3, 2024

Keywords

ClinConnect Summary

This clinical trial, titled the Indonesian Study of Vonoprazan vs. Esomeprazole in Erosive Esophagitis, is designed to compare the effectiveness of two medications: vonoprazan and esomeprazole. Both drugs aim to relieve early symptoms in patients suffering from erosive esophagitis, a condition where the lining of the esophagus becomes inflamed and damaged. The study will help researchers understand how well each medication works and how safe they are for patients in Indonesia.

To participate, individuals must be over 18 years old and have been diagnosed with erosive esophagitis through an endoscopy. They should also have a specific score indicating the severity of their symptoms. Participants will take either vonoprazan (20 mg) or esomeprazole (40 mg) once a day for two weeks and will visit the clinic weekly for follow-ups. They will also keep a diary to track any side effects or changes in their symptoms. It’s important to note that individuals with certain medical conditions, allergies, or a history of surgery related to the esophagus or stomach will not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged \>18 years with a GERD-Q score of 8.
• • Diagnosed with erosive esophagitis by endoscopy. (Los Angeles Classification A-D)
• • Patients are willing to undergo a series of therapeutic management.
• Exclusion Criteria:
• • Patients with a history of allergy to PCAB or PPI groups.
• • Patients with gastric and/or duodenal ulcers.
• • Patients with Helicobacter pylori infection.
• • Patients with a history of significant systemic disease disorders affecting the esophagus and stomach.
• • Patients with a history of malignant disease related to the esophagus and/or stomach.
• • Patients with a history of esophageal and/or gastric surgery.
• • Pregnant patients